ASE-9285-1 Human NK cells, iPSC-derived, P0

Scale-up screening and conduct cell-based assays using NK cells with a uniform genetic background with ASE-9285-1, passage 0 (P0) iPSC-derived NK cells.

These cells are derived from ASE-9211, our control iPSC cell line reprogrammed from normal male fibroblasts using an episomal method.

Quality control assays
Each lot of ASE-9285-1 meets the following standards before release

• ≥ 80% purity using flow cytometry and NK cell markers CD45 and CD56
• Each lot tested growth, viability, and the absence of mycoplasma and pathogens

Kit components
Each kit contains cells and optimized media:

• 1 vial of P0 iPSC-derived NK cells, ≥1 x 10⁶ cells/ vial
• 100 mL of NK Cell Basal Culture Media (for cytotoxicity assays only, at this time)
• 1 mL of NK Cell Culture Media Supplement A (100x)

iPSC-derived NK cells show tumor cell killing activity

iPSC-derived NK cells (ASE9285-1) display robust activity against hematopoietic tumor cell line K562. We mixed Calcein AM-stained K562 cells (target) with ASE-9285-1 NK cells (effector) at effector/target (E/T) ratios ranging from 0.625—5, incubated for 16 hours, and measured fluorescence.

Each lot of iPSC-derived NK cells is ≥ 80% NK cells

Flow cytometry analysis of ASE-9285-1 iPSC-derived NK cells for NK cell biomarkers. Cryopreserved NK cells, differentiated from Applied StemCell’s control iPSC line, ASE-9211, were recovered in NK culture media. The cells were stained with NK cell markers, CD45 and CD56, at day 2.